GRI Bio, Inc. Income Statement
GRI|1 years of annual SEC 10-K data (FY2021-FY2021)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
GRI Bio, Inc. reported $100,000 in revenue and $5M in net loss for FY2021. Its profit margin was -4822.0% in FY2021.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 |
|---|---|
| Revenue | $100.0K |
| SG&A Expense | $1.2M |
| R&D Expense | $3.7M |
| Operating Income | -$4.8M |
| Net Income | -$4.8M |
| EPS (Basic) | -$1.07 |
| EPS (Diluted) | -$1.07 |
| Shares Outstanding | 4.5M |
| Operating Margin | -4788.0% |
| Profit Margin | -4822.0% |